John R. Neefe

2.2k total citations
51 papers, 888 citations indexed

About

John R. Neefe is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, John R. Neefe has authored 51 papers receiving a total of 888 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Immunology and 15 papers in Molecular Biology. Recurrent topics in John R. Neefe's work include Immunotherapy and Immune Responses (9 papers), T-cell and B-cell Immunology (6 papers) and Hepatitis B Virus Studies (5 papers). John R. Neefe is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), T-cell and B-cell Immunology (6 papers) and Hepatitis B Virus Studies (5 papers). John R. Neefe collaborates with scholars based in United States, United Kingdom and Netherlands. John R. Neefe's co-authors include Stephen E. Goldstone, Joel M. Palefsky, Geoffrey R. Weiss, Laura F. Hutchins, Philip S. Schein, Robert B. Livingston, Charles W. Taylor, Frederick P. Smith, John Crowley and Steven M. Grunberg and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

John R. Neefe

49 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John R. Neefe United States 18 281 249 248 208 159 51 888
Nanette McAtee United States 12 377 1.3× 206 0.8× 128 0.5× 169 0.8× 241 1.5× 16 1.0k
T Ohnoshi Japan 14 308 1.1× 100 0.4× 200 0.8× 159 0.8× 192 1.2× 92 721
G. D. Cummings United States 10 136 0.5× 73 0.3× 239 1.0× 152 0.7× 89 0.6× 11 674
S A Rosenberg United States 8 264 0.9× 336 1.3× 62 0.3× 161 0.8× 223 1.4× 10 946
Phillip Periman United States 13 293 1.0× 254 1.0× 76 0.3× 180 0.9× 147 0.9× 26 693
Martin W. Oster United States 13 404 1.4× 455 1.8× 252 1.0× 163 0.8× 228 1.4× 30 1.4k
F Invernizzi Italy 14 238 0.8× 97 0.4× 236 1.0× 303 1.5× 86 0.5× 39 1.0k
Terrence Moore United States 8 434 1.5× 84 0.3× 181 0.7× 241 1.2× 148 0.9× 12 903
Elizabeth B. Harvey United States 13 446 1.6× 169 0.7× 160 0.6× 210 1.0× 262 1.6× 16 1.3k
Georg Pall Austria 17 362 1.3× 166 0.7× 75 0.3× 195 0.9× 161 1.0× 49 811

Countries citing papers authored by John R. Neefe

Since Specialization
Citations

This map shows the geographic impact of John R. Neefe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Neefe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Neefe more than expected).

Fields of papers citing papers by John R. Neefe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Neefe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Neefe. The network helps show where John R. Neefe may publish in the future.

Co-authorship network of co-authors of John R. Neefe

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Neefe. A scholar is included among the top collaborators of John R. Neefe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Neefe. John R. Neefe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Derkay, Craig S., Richard J. Smith, John E. McClay, et al.. (2005). HspE7 Treatment of Pediatric Recurrent Respiratory Papillomatosis: Final Results of an Open-Label Trial. Annals of Otology Rhinology & Laryngology. 114(9). 730–737. 63 indexed citations
2.
Goldstone, Stephen E., et al.. (2002). Activity of HspE7, a Novel Immunotherapy, in Patients with Anogenital Warts. Diseases of the Colon & Rectum. 45(4). 502–507. 69 indexed citations
3.
Kish, Julie A., Michael Wolf, E. David Crawford, et al.. (1994). Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study. Cancer. 74(3). 916–919. 39 indexed citations
4.
Buys, Saundra S., Barbara Metch, Stanley P. Balcerzak, John R. Neefe, & W. J. Stuckey. (1994). Phase II Evaluation of Amonafide in Advanced Sarcoma: A Southwest Oncology Group Study. Cancer Investigation. 12(4). 399–402. 2 indexed citations
5.
Livingston, Robert B., John J. Crowley, Stephen K. Williamson, et al.. (1993). Prolonged, alternating chemotherapy for extensive small cell lung cancer. A southwest oncology group study. Cancer. 71(11). 3509–3513. 3 indexed citations
6.
Gandara, David R., John Crowley, Robert B. Livingston, et al.. (1993). Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.. Journal of Clinical Oncology. 11(5). 873–878. 121 indexed citations
7.
John, William J., et al.. (1993). 5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules. Cancer. 72(11). 3191–3195. 9 indexed citations
8.
Brown, Thomas D., Phyllis J. Goodman, John S. Macdonald, et al.. (1991). Phase II Trial of Recombinant DNA ?? -Interferon in Advanced Colorectal Cancer: A Southwest Oncology Group Study. Journal of Immunotherapy. 10(5). 379–382. 4 indexed citations
9.
Neefe, John R. & Jacob L. Glass. (1991). Abrogation of interferon-induced resistance to interferon-activated major histocompatibility complex-unrestricted killers by treatment of a melanoma cell line with 5-fluorouracil.. PubMed. 51(12). 3159–63. 16 indexed citations
10.
Neefe, John R. & William J. John. (1991). Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors.. PubMed. 18(5 Suppl 7). 77–82. 16 indexed citations
11.
Whitehead, Robert P., Thomas R. Fleming, John S. Macdonald, et al.. (1990). A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.. PubMed. 9(6). 588–91. 21 indexed citations
12.
Neefe, John R., et al.. (1989). LACK OF COMMON HAPLOTYPE AMONG FOUR FAMILY MEMBERS WITH LATE‐ONSET KAPOSI'S SARCOMA. International Journal of Immunogenetics. 16(3). 247–250. 2 indexed citations
13.
Treat, Joseph, Paul V. Woolley, James D. Ahlgren, et al.. (1989). Therapy of Advanced Gastric Carcinoma. American Journal of Clinical Oncology. 12(2). 162–168. 3 indexed citations
14.
Ahlgren, James D., et al.. (1984). A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer. 54(10). 2257–2261. 30 indexed citations
15.
Neefe, John R., et al.. (1982). Phase II trial of mitoxantrone in advanced colorectal cancer.. PubMed. 66(11). 1995–6. 4 indexed citations
16.
Neefe, John R. & David H. Sachs. (1976). Specific elimination of cytotoxic effector cells. I. Adsorptive behavior of effectors and their precursors and spleen cell monolayers.. The Journal of Experimental Medicine. 144(4). 996–1008. 16 indexed citations
17.
Krueger, G. R. F., et al.. (1975). Pathology of modified graft-versus-host disease in bone marrow allografted monkeys treated with antilymphocyte serum. Annals of Hematology. 30(1). 19–30. 3 indexed citations
18.
Neefe, John R., Ethan Ellis, & G. Nicholas Rogentine. (1975). Rhesus Lymphocyte Alloantigens.III.Identification of New Antigens. Tissue Antigens. 6(3). 195–204. 7 indexed citations
19.
Neefe, John R., et al.. (1955). PREVALENCE AND NATURE OF HEPATIC DISTURBANCE FOLLOWING ACUTE VIRAL HEPATITIS WITH JAUNDICE. Annals of Internal Medicine. 43(1). 1–32. 32 indexed citations
20.
Bluemle, Lewis W., et al.. (1955). The Clinical Usefulness of Acth and Cortisone in Liver Disease. Gastroenterology. 28(5). 745–758. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nanette McAtee Breakdown of academic impact, for papers by T Ohnoshi Breakdown of academic impact, for papers by G. D. Cummings Breakdown of academic impact, for papers by S A Rosenberg Breakdown of academic impact, for papers by Phillip Periman Breakdown of academic impact, for papers by Martin W. Oster Breakdown of academic impact, for papers by F Invernizzi Breakdown of academic impact, for papers by Terrence Moore Breakdown of academic impact, for papers by Elizabeth B. Harvey Breakdown of academic impact, for papers by Georg Pall
Rankless by CCL
2026